13F-HR: Gilead Sciences, Inc. Reveals Q1 2025 Investment Portfolio

Gilead Sciences, Inc. discloses its holdings as of March 31, 2025, showcasing significant investments in various biotechnology companies.

Summary

• Gilead Sciences, Inc. has filed its Form 13F for the quarter ended March 31, 2025.
• The report details the company's holdings in various publicly traded companies.
• The total value of the reported holdings amounts to $1,181,331,731.
• The filing includes information on 14 different holdings.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document is a standard portfolio disclosure. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information about Gilead's investment positions.

Positives

• Gilead Sciences maintains a diversified investment portfolio across multiple biotechnology companies.
• The large portfolio value suggests a strong financial position and active investment strategy.

Risks

• The value of Gilead's holdings is subject to market fluctuations and the performance of the individual companies in which it invests.
• Investments in biotechnology companies carry inherent risks related to drug development, regulatory approvals, and market competition.

Future Outlook

The document does not contain specific forward-looking statements, but the investment portfolio reflects Gilead's strategic interests in the biotechnology sector.

Management Comments

• Andrew D. Dickinson, Executive Vice President and Chief Financial Officer, signed the report on behalf of Gilead Sciences, Inc.

Industry Context

Gilead's investment portfolio provides insight into the company's strategic interests and potential future collaborations within the biotechnology industry, reflecting trends in targeted therapies and innovative drug development.

Comparison to Industry Standards

• Comparing Gilead's investment strategy to other major pharmaceutical companies like Johnson & Johnson or Pfizer, one can observe differences in portfolio composition and investment focus.
• For example, while Gilead has significant holdings in companies like Arcellx and Galapagos, other companies may prioritize investments in different therapeutic areas or stages of drug development.
• Benchmarking against venture capital firms specializing in biotechnology, such as Flagship Pioneering or ARCH Venture Partners, could provide further context on the risk-return profile of Gilead's investments.

Stakeholder Impact

• Shareholders can use this information to understand Gilead's investment strategy and exposure to various biotechnology companies.
• The investments can impact the valuation and future prospects of the companies in which Gilead holds a stake.

Key Dates

Keywords

Form 13F, Gilead Sciences, Holdings, Investments, Portfolio, Biotechnology